Interleukin (IL)-12 and IL-23 and Their Conflicting Roles in Cancer
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
The balance of proinflammatory cytokines interleukin (IL)-12 and IL-23 plays a key role in shaping the development of antitumor or protumor immunity. In this review, we discuss the role IL-12 and IL-23 plays in tumor biology from preclinical and clinical data. In particular, we discuss the mechanism by which IL-23 promotes tumor growth and metastases and how the IL-12/IL-23 axis of inflammation can be targeted for cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · cited 2×
“Similarly, a role for IL-23 has also been shown for the T-cell-mediated tumor dormancy phase (equilibrium) of cancer immunoediting (Schreiber et al. 2011), best characterized in the MCA-induced fibrosarcoma model (Koebel et al.”
BackgroundSelf-citationIvanov, I. I., McKenzie, B. S., Zhou, L., Tadokoro, C. E., Lepelley, A., Lafaille, J. J., Cua, D. J., & Littman, D. R. (2006) · Cell · doi:10.1016/j.cell.2006.07.035 · Cited by 5,145
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation
Langrish, C. L., Chen, Y., Blumenschein, W. M., Mattson, J., Basham, B., Sedgwick, J. D., McClanahan, T., Kastelein, R. A., & Cua, D. J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041257 · Cited by 4,099 · cited 1×
“In contrast, IL-23 plays an important role in promoting the proliferation and effector function of Th17 cells, which are characterized by expression of the IL-17 family cytokines (Aggarwal et al. 2003; Langrish et al. 2004; Langrish et al. 2005).”
BackgroundCua, D. J., Sherlock, J., Chen, Y., Murphy, C. A., Joyce, B., Seymour, B., Lucian, L., To, W., Kwan, S., Churakova, T., et al. (2003) · Nature · doi:10.1038/nature01355 · Cited by 2,906 · cited 3×
“12) stimulated with anti-CD3 and anti-CD28 Thymus Naı̈ve B6 qPCR Coquet et al. 2008 DC (CD11cþ) Spleen, LN Naı̈ve B6, naı̈ve IL-23R GFP B6 qPCR, FC Awasthi et al. 2009, ElBehi et al. 2011 Macrophage (CD11bþ) LN, LP Naı̈ve IL-23R GFP B6 FC Awasthi et al. 2009 Inflammatory macrophage (CD42 CD11bþ CD45þ) CNS EAE B6 qPCR…”
BackgroundInflammation-induced cancer: Crosstalk between tumours, immune cells and microorganisms
Elinav, E., Nowarski, R., Thaiss, C. A., Hu, B., Jin, C., & Flavell, R. A. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3611 · Cited by 2,000
Wu, S., Rhee, K.-J., Albesiano, E., Rabizadeh, S., Wu, X., Yen, H.-R., Huso, D. L., Brancati, F. L., Wick, E., McAllister, F., et al. (2009) · Nature Medicine · doi:10.1038/nm.2015 · Cited by 1,812
Interferons, immunity and cancer immunoediting
Dunn, G. P., Koebel, C. M., & Schreiber, R. D. (2006) · Nature Reviews Immunology · doi:10.1038/nri1961 · Cited by 1,617
The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing
Gaffen, S. L., Jain, R., Garg, A. V., & Cua, D. J. (2014) · Nature reviews. Immunology · doi:10.1038/nri3707 · Cited by 1,585 · cited 2×
“In mice and humans, a range of innate and adaptive immune cells have been shown to express IL-12 and IL-23 receptors constitutively as measured by qPCR, flow cytometry, or using an IL-23R GFP KI reporter mouse (Tables 3 and 4), although they appear to be expressed at varying levels, which can be further up-regulated f…”
BackgroundMethodSutton, C. E., Lalor, S. J., Sweeney, C. M., Brereton, C. F., Lavelle, E. C., & Mills, K. H. G. (2009) · Immunity · doi:10.1016/j.immuni.2009.08.001 · Cited by 1,553
Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice
Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., & Schreiber, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7556 · Cited by 1,465 · cited 1×
“Mice that were deficient for IL-12/23p40 or IFN-g and challenged with methylcholanthrene-A (MCA), a chemical carcinogen, displayed increased rate and frequency of tumor growth compared to wild-type (WT) controls (Kaplan et al. 1998; Smyth et al. 2000).”
BackgroundGeneration of pathogenic TH17 cells in the absence of TGF-β signalling
Ghoreschi, K., Laurence, A., Yang, X.-P., Tato, C. M., McGeachy, M. J., Konkel, J. E., Ramos, H. L., Wei, L., Davidson, T. S., Bouladoux, N., et al. (2010) · Nature · doi:10.1038/nature09447 · Cited by 1,388
Adenoma–linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth
Grivennikov, S. I., Wang, K., Mucida, D., Stewart, C. A., Schnabl, B., Jauch, D., Taniguchi, K., Yu, G.-Y., Österreicher, C. H., Hung, K. E., et al. (2012) · Nature · doi:10.1038/nature11465 · Cited by 1,327 · cited 4×
“In two other de novo mouse models of colon carcinogenesis (CPC-APC, ApcMin/þ), IL-23 and IL-17A both had tumorpromoting effects as loss of IL-23/IL-23R/ IL-17R or IL-23R/IL-17A blockade resulted in reduced tumor load (Wu et al. 2009; Grivennikov et al. 2012).”
BackgroundInfluentialEl-Behi, M., Ciric, B., Dai, H., Yan, Y., Cullimore, M., Safavi, F., Zhang, G.-X., Dittel, B. N., & Rostami, A. (2011) · Nature Immunology · doi:10.1038/ni.2031 · Cited by 1,071 · cited 2×
“…Naı̈ve IL-23R GFP B6 FC Awasthi et al. 2009; Chognard et al. 2014 Th17 cells (CD4þ) cultured in in vitro Th17 conditions Spleen Naı̈ve B6 qPCR Ciric et al. 2009; El-Behi et al. 2011 LTi cells (CD32 CD4þ) LP Naı̈ve IL-23R GFP B6 FC Awasthi et al. 2009 Treg (CD4þ FOXP3þ) Tumor, DLN B16, MC38 and…”
BackgroundShen, P., Roch, T., Lampropoulou, V., O’Connor, R. A., Stervbo, U., Hilgenberg, E., Ries, S., Dang, V. D., Jaimes, Y., Daridon, C., et al. (2014) · Nature · doi:10.1038/nature12979 · Cited by 1,048 · cited 1×
“Given that IL-12p35 is also used as a shared subunit by the inhibitory cytokine IL-35 (IL-12p35/Ebi3 [IL27p28]) produced by Tregs and B cells (Collison et al. 2007; Shen et al. 2014), one must also consider how the balance between IL-12 and IL-35 impacts on tumorigenesis (Banchereau et al. 2012).”
BackgroundIL-23 promotes tumour incidence and growth
Langowski, J. L., Zhang, X., Wu, L., Mattson, J. D., Chen, T., Smith, K., Basham, B., McClanahan, T., Kastelein, R. A., & Oft, M. (2006) · Nature · doi:10.1038/nature04808 · Cited by 1,018 · cited 6×
“…(TPA)-promoted two-stage skin carcinogenesis, IL-12/23p40-deficient and IL-23-p19-deficient mice displayed significantly decreased numbers of carcinogen-induced papillomas compared to WT mice, whereas the opposite was observed in IL-12p35-deficient mice (Langowski et al. 2006).”
BackgroundResultInfluentialCombination cancer immunotherapies tailored to the tumour microenvironment
Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.209 · Cited by 944 · cited 1×
“In the past 5 years, therapies targeting T-cell immune checkpoint receptors have achieved remarkable success in the clinic, particularly in combination, and will increasingly become incorporated into standard-of-care for many cancer types (Smyth et al. 2016).”
BackgroundSelf-citation
Cited by
Garris, C. S., Arlauckas, S. P., Kohler, R. H., Trefny, M. P., Garren, S., Piot, C., Engblom, C., Pfirschke, C., Siwicki, M., Gungabeesoon, J., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.09.024 · Cited by 966
Interleukin-6 Family Cytokines
Rose-John, S. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028415 · Cited by 799
Interleukins in cancer: from biology to therapy
Briukhovetska, D., Dörr, J., Endres, S., Libby, P., Dinarello, C. A., & Kobold, S. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00363-z · Cited by 781
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets
Tie, Y., Tang, F., Wei, Y.-Q., & Wei, X.-W. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01282-8 · Cited by 591
The Immunobiology of the Interleukin-12 Family: Room for Discovery
Tait Wojno, E. D., Hunter, C. A., & Stumhofer, J. S. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.011 · Cited by 482
Metadata
- Authors
- Yan, J., Smyth, M. J., & Teng, M. W. L.
- Venue
- Cold Spring Harbor Perspectives in Biology
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2017-07-17
- Volume
- 10
- Issue
- 7
- Pages
- a028530
- ISSN
- 1943-0264 (ISSN-L)
- OpenAlex
- W2736048325
- Cited by
- 149
- References
- 17
- Type
- posted content
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.